LDL-apheresis with dextran sulphate and anaphylactoid reactions to ACE inhibitors

Coronary heart disease (CHD) is the leading cause of death in the United States. Dyslipidemias, like decreased high-density lipoprotein (HDL) and increased low-density lipoprotein (LDL), have been linked through epidemiologic and experimental studies with the development of atherosclerosis and an increased risk of CHD. The introduction of various classes of lipid-lowering drugs, especially the hydroxymethylglutaryl-coenzyme-A-reductase inhibitors (statins), has allowed for effective treatment of hyperlipidemia. This article reviews the following nonpharmacologic approaches to hyperlipidemia: LDL apheresis, surgery, the emergence of HDL as a therapeutic target, gene therapy, and finally, the possibility of developing a vaccine against atherosclerosis.

show abstract

“…There are reports that this reaction may be prevented by discontinuation of ACE inhibitors 24 hours before LDL apheresis. 42,43 …”

Section: Side Effects and Cautionary Measuresmentioning

confidence: 98%

Nonpharmacologic Approaches for the Treatment of Hyperlipidemia

Kermani

Frishman²

2005

Cardiology in Review

View full text Add to dashboard Cite

show abstract

“…Cristina Arbona (B). pudiendo reiniciarlo al terminar la sesión 53 . En pacientes muy jóvenes 54,55 el acceso venoso suele un problema, siendo necesario la colocación de un catéter venoso central; por ello, a las complicaciones del procedimiento debemos añadir sus posibles efectos secundarios, infección y trombosis 52 .…”

Section: Aféresis De Ldlunclassified

Hipercolesterolemia familiar homocigota: adaptación a España del documento de posición del grupo de consenso sobre hipercolesterolemia familiar de la Sociedad Europea de Arteriosclerosis. Documento de Consenso de la Sociedad Española de Arteriosclerosis (SEA) y la Fundación Hipercolesterolemia Familiar (FHF)

Ascaso

Mata²,

Arbona

et al. 2015

Clínica e Investigación en Arteriosclerosis

View full text Add to dashboard Cite

“…Anaphylactoid reactions have been reported in patients treated with LDL-aph using DS columns [2]. These reactions have been attributed to the release of bradykinin, a potent vasodilator.…”

mentioning

confidence: 99%

“…ACE inhibitors do not decrease rHuEpo response in patients with end-stage renal failure Sir, Angiotensin-converting enzyme (ACE) inhibitors have been successfully utilized to reduce haemoglobin concentrations in patients with post-transplant erythrocytosis [1,2]. Some authors have suggested that ACE inhibitors could decrease serum erythropoietin levels [3] and bone-marrow erythropoiesis in ESRD [4].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Complement activation by LDL-apheresis using dextran sulphate

Pascual

Blanc²,

1995

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

LettersHCV-RNA, is not yet routinely available and is limited by false-positive or false-negative results.Meanwhile, in order to reduce the incidence of HCV infection, strict adherence to the universal precautions (CDC, Atlanta) must be carried out. According to current knowledge the application of these measures of hygiene is probably sufficient to prevent HCV spread in the dialysis setting, and the isolation of positive patients is not warranted.

show abstract

LDL-apheresis with dextran sulphate and anaphylactoid reactions to ACE inhibitors

Cited by 41 publications

References 5 publications

Nonpharmacologic Approaches for the Treatment of Hyperlipidemia

Nonpharmacologic Approaches for the Treatment of Hyperlipidemia

Complement activation by LDL-apheresis using dextran sulphate

Contact Info

Product

Resources

About